Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells
- PMID: 1563103
- PMCID: PMC1554377
- DOI: 10.1111/j.1365-2249.1992.tb03032.x
Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells
Abstract
HIV-1 envelope glycoprotein (gp120), as a CD4-binding reactant, has been shown to inhibit in its native form human T cell responses to several antigens. Here we show that gp120 in soluble form also inhibits activation of a specific human T cell line that responds to gp120-pulsed autologous antigen-presenting cells. In addition the inhibitory property of gp120 for antigen-driven T cell proliferation depends upon its ability to bind CD4 and is lost when CD4-binding capacity is abolished by denaturation, or blocked by complexing with soluble CD4 or with polyclonal antibodies. In contrast, antigenicity of denatured or complexed gp120 for specific human T cells is preserved. Similar effects are also observed with another CD4-binding reactant (i.e. anti-Leu 3a MoAb), which stimulates and/or inhibits human T cells specific for mouse immunoglobulins depending on native or denatured conformation.
Similar articles
-
Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):893-905. doi: 10.1089/08892220050042837. AIDS Res Hum Retroviruses. 2000. PMID: 10875615
-
Non-covalent complexes of HIV gp120 with CD4 and/or mAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production.Int Immunol. 1993 Sep;5(9):1109-17. doi: 10.1093/intimm/5.9.1109. Int Immunol. 1993. PMID: 7902128
-
Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120.J Virol. 2001 Nov;75(22):10950-7. doi: 10.1128/JVI.75.22.10950-10957.2001. J Virol. 2001. PMID: 11602735 Free PMC article.
-
Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.Crit Rev Immunol. 1988;8(4):315-39. Crit Rev Immunol. 1988. PMID: 2850890 Review.
-
Molecular interactions between HIV and the T lymphocyte.Biochim Biophys Acta. 1990 Nov 14;1096(1):10-3. doi: 10.1016/0925-4439(90)90005-a. Biochim Biophys Acta. 1990. PMID: 2268680 Review. No abstract available.
Cited by
-
Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.Clin Exp Immunol. 1994 Sep;97(3):361-6. doi: 10.1111/j.1365-2249.1994.tb06095.x. Clin Exp Immunol. 1994. PMID: 7915974 Free PMC article.
-
Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule.J Clin Invest. 1997 Jan 15;99(2):257-66. doi: 10.1172/JCI119154. J Clin Invest. 1997. PMID: 9005994 Free PMC article.
-
Cultured human Langerhans' cells are superior to fresh cells at presenting native HIV-1 protein antigens to specific CD4+ T-cell lines.Immunology. 1996 Feb;87(2):310-6. Immunology. 1996. PMID: 8698396 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials